Compare WRBY & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRBY | ITGR |
|---|---|---|
| Founded | 2010 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2021 | 2000 |
| Metric | WRBY | ITGR |
|---|---|---|
| Price | $24.08 | $82.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $26.50 | ★ $91.14 |
| AVG Volume (30 Days) | ★ 3.1M | 847.9K |
| Earning Date | 06-01-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.88 | N/A |
| EPS | 0.01 | ★ 2.89 |
| Revenue | $871,905,000.00 | ★ $1,853,637,000.00 |
| Revenue This Year | $14.81 | $1.69 |
| Revenue Next Year | $15.98 | $6.53 |
| P/E Ratio | $2,354.00 | ★ $28.84 |
| Revenue Growth | ★ 13.04 | 7.98 |
| 52 Week Low | $13.63 | $62.00 |
| 52 Week High | $31.00 | $127.56 |
| Indicator | WRBY | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 44.24 |
| Support Level | $21.47 | $82.78 |
| Resistance Level | $24.90 | $87.54 |
| Average True Range (ATR) | 1.74 | 2.73 |
| MACD | -0.05 | -0.43 |
| Stochastic Oscillator | 38.48 | 14.66 |
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.